Please assess the completion status of the following clinical trial:

Trial Title: A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
INCLUSION CRITERIA - For Parts 1-4:~* Histologically confirmed diagnosis of a locally advanced (not amenable to curative therapy such as surgical resection) or metastatic solid tumors~* Life expectancy \> 12 weeks~* Patients must not have received prior interleukin-2 (IL-2) therapy~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Measurable disease per RECIST 1.1~* Patients with stable brain metastases under certain criteria~* Fresh and archival tumor tissue available Tumor specific inclusion criteria may apply.~EXCLUSION CRITERIA - For Parts 1-4:~* Use of an investigational agent or an investigational device within 28 days before administration of first dose of NKTR--214~* Females who are pregnant or breastfeeding~* Participants who have an active autoimmune disease requiring systemic treatment within the past 3 months or have a documented history of clinically severe autoimmune disease that requires systemic steroids or immunosuppressive agents~* History of organ transplant that requires use of immune suppressive agents~* Active malignancy not related to the current diagnosed malignancy~* Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis~* Participants who have had \< 28 days since the last chemotherapy, biological therapy, or \< 14 days from approved tyrosine kinase inhibitor (TKI) therapy, or systemic or inhaled steroid therapy at doses greater than 10mg of prednisone Tumor specific exclusion criteria may apply.~Other protocol defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Escalation: Combination of NKTR-214 + nivolumab (Type: EXPERIMENTAL): NKTR 214 + nivolumab at 5 dosage levels to determine the RP2D Part 1 of RP2D in patients with advanced or metastatic melanoma, RCC, NSCLC, urothelial carcinoma, or TNBC.
- Dose Expansion: Combination of NKTR-214 + nivolumab (Type: EXPERIMENTAL): NKTR-214+nivolumab in patients with advanced or metastatic solid tumor malignancies to assess the efficacy of the RP2D.
- Experimental: Combination of NKTR-214 + nivolumab + ipilimumab (Type: EXPERIMENTAL): To assess the safety and tolerability of NKTR 214 + nivolumab + ipilimumab triplet therapy and establish RP2D dosing schedules for Part 4 in patients with advanced or metastatic melanoma, RCC, NSCLC, or UCC in a first-line setting (1L).
- Experimental: Dose Expansion of Part 3 (Type: EXPERIMENTAL): To further assess the RP2D triplet combination dosing schedules from Part 3 in 1L NSCLC and 1L RCC patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete